Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2

Adv Sci (Weinh). 2022 Jul;9(20):e2201378. doi: 10.1002/advs.202201378. Epub 2022 May 11.

Abstract

Inhibitors of viral cell entry based on poly(styrene sulfonate) and its core-shell nanoformulations based on gold nanoparticles are investigated against a panel of viruses, including clinical isolates of SARS-CoV-2. Macromolecular inhibitors are shown to exhibit the highly sought-after broad-spectrum antiviral activity, which covers most analyzed enveloped viruses and all of the variants of concern for SARS-CoV-2 tested. The inhibitory activity is quantified in vitro in appropriate cell culture models and for respiratory viral pathogens (respiratory syncytial virus and SARS-CoV-2) in mice. Results of this study comprise a significant step along the translational path of macromolecular inhibitors of virus cell entry, specifically against enveloped respiratory viruses.

Keywords: SARS-CoV-2; broad-spectrum antivirals; entry inhibitors; in vivo; macromolecules; polyanions; respiratory syncytial virus (RSV).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Gold
  • Metal Nanoparticles*
  • Mice
  • SARS-CoV-2
  • Virus Internalization

Substances

  • Antiviral Agents
  • Gold